Overview

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose compared to placebo and moxifloxacin (a positive control in healthy adult men and women.

Phase:

Phase 1

Details

Lead Sponsor:

CardioKine Inc.

Collaborators:

Biogen
Cardiokine Biopharma, LLC

Treatments:

Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination